ALN-PCSsc: Phase I started

Alnylam began a single-blind, placebo-controlled, U.K. Phase I trial to evaluate subcutaneous ALN-PCSsc in up to

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE